Reported Earnings • Apr 28
Third quarter 2026 earnings released: EPS: PK₨8.71 (vs PK₨8.71 in 3Q 2025) Third quarter 2026 results: EPS: PK₨8.71 (in line with 3Q 2025). Revenue: PK₨7.39b (up 6.4% from 3Q 2025). Net income: PK₨550.4m (flat on 3Q 2025). Profit margin: 7.4% (down from 7.9% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 16
Shifa International Hospitals Limited to Report Q3, 2026 Results on Apr 25, 2026 Shifa International Hospitals Limited announced that they will report Q3, 2026 results at 9:30 AM, Pakistan Standard Time on Apr 25, 2026 New Risk • Mar 30
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: PK₨27.4b (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 25
Second quarter 2026 earnings released: EPS: PK₨13.62 (vs PK₨9.83 in 2Q 2025) Second quarter 2026 results: EPS: PK₨13.62 (up from PK₨9.83 in 2Q 2025). Revenue: PK₨7.77b (up 13% from 2Q 2025). Net income: PK₨860.8m (up 39% from 2Q 2025). Profit margin: 11% (up from 9.1% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 13
Shifa International Hospitals Limited to Report First Half, 2026 Results on Feb 21, 2026 Shifa International Hospitals Limited announced that they will report first half, 2026 results on Feb 21, 2026 Buy Or Sell Opportunity • Nov 12
Now 21% overvalued Over the last 90 days, the stock has fallen 10% to PK₨505. The fair value is estimated to be PK₨417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 30%. Buy Or Sell Opportunity • Oct 14
Now 21% overvalued Over the last 90 days, the stock has fallen 1.6% to PK₨540. The fair value is estimated to be PK₨445, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 26%. Reported Earnings • Oct 09
Full year 2025 earnings released: EPS: PK₨35.72 (vs PK₨21.64 in FY 2024) Full year 2025 results: EPS: PK₨35.72 (up from PK₨21.64 in FY 2024). Revenue: PK₨28.0b (up 19% from FY 2024). Net income: PK₨2.26b (up 65% from FY 2024). Profit margin: 8.1% (up from 5.8% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Oct 08
Upcoming dividend of PK₨5.00 per share Eligible shareholders must have bought the stock before 15 October 2025. Payment date: 14 November 2025. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Pakistani dividend payers (7.3%). Lower than average of industry peers (1.8%). Buy Or Sell Opportunity • Sep 26
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to PK₨547. The fair value is estimated to be PK₨445, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 26%. Declared Dividend • Sep 10
Dividend of PK₨5.00 announced Shareholders will receive a dividend of PK₨5.00. Ex-date: 15th October 2025 Payment date: 14th November 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.7%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 13%. Reported Earnings • Sep 09
Full year 2025 earnings released: EPS: PK₨35.72 (vs PK₨21.64 in FY 2024) Full year 2025 results: EPS: PK₨35.72 (up from PK₨21.64 in FY 2024). Revenue: PK₨28.4b (up 20% from FY 2024). Net income: PK₨2.26b (up 65% from FY 2024). Profit margin: 8.0% (up from 5.8% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Aug 04
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 35% to PK₨548. The fair value is estimated to be PK₨453, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 20%. Buy Or Sell Opportunity • Jul 08
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 27% to PK₨560. The fair value is estimated to be PK₨453, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 20%. Valuation Update With 7 Day Price Move • May 15
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to PK₨458, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 164% over the past three years. New Risk • Apr 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: PK₨27.8b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to PK₨489, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 21x in the Healthcare industry in Asia. Total returns to shareholders of 175% over the past three years. New Risk • Jan 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Pakistani stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Market cap is less than US$100m (PK₨25.3b market cap, or US$90.8m). Reported Earnings • Oct 31
First quarter 2025 earnings released: EPS: PK₨10.18 (vs PK₨5.93 in 1Q 2024) First quarter 2025 results: EPS: PK₨10.18 (up from PK₨5.93 in 1Q 2024). Revenue: PK₨7.06b (up 19% from 1Q 2024). Net income: PK₨643.6m (up 72% from 1Q 2024). Profit margin: 9.1% (up from 6.3% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to PK₨247, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 23x in the Healthcare industry in Asia. Total returns to shareholders of 38% over the past three years. Upcoming Dividend • Oct 10
Upcoming dividend of PK₨2.50 per share Eligible shareholders must have bought the stock before 17 October 2024. Payment date: 18 November 2024. Trailing yield: 2.5%. Lower than top quartile of Pakistani dividend payers (11%). Higher than average of industry peers (1.7%). Valuation Update With 7 Day Price Move • Sep 23
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to PK₨183, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 24x in the Healthcare industry in Asia. Total loss to shareholders of 5.0% over the past three years. Declared Dividend • Sep 19
Final dividend of PK₨2.50 announced Shareholders will receive a dividend of PK₨2.50. Ex-date: 17th October 2024 Payment date: 18th November 2024 Dividend yield will be 2.5%, which is higher than the industry average of 1.7%. Payout Ratios Payout ratio: 18%. Cash payout ratio: 12%. Announcement • Sep 18
Shifa International Hospitals Limited, Annual General Meeting, Oct 28, 2024 Shifa International Hospitals Limited, Annual General Meeting, Oct 28, 2024. Location: at the registered office of the company, at sector h-8/4, islamabad Pakistan Valuation Update With 7 Day Price Move • Sep 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to PK₨149, the stock trades at a trailing P/E ratio of 9x. Average trailing P/E is 23x in the Healthcare industry in Asia. Total loss to shareholders of 27% over the past three years. Reported Earnings • May 02
Third quarter 2024 earnings released: EPS: PK₨5.12 (vs PK₨8.79 in 3Q 2023) Third quarter 2024 results: EPS: PK₨5.12 (down from PK₨8.79 in 3Q 2023). Revenue: PK₨5.82b (up 12% from 3Q 2023). Net income: PK₨323.4m (down 42% from 3Q 2023). Profit margin: 5.6% (down from 11% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 01
Upcoming dividend of PK₨1.50 per share Eligible shareholders must have bought the stock before 08 May 2024. Payment date: 31 May 2024. Payout ratio is a comfortable 7.4% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of Pakistani dividend payers (13%). Lower than average of industry peers (1.7%). Reported Earnings • Mar 03
Second quarter 2024 earnings released: EPS: PK₨5,590 (vs PK₨3.71 in 2Q 2023) Second quarter 2024 results: EPS: PK₨5,590 (up from PK₨3.71 in 2Q 2023). Revenue: PK₨6.14b (up 28% from 2Q 2023). Net income: PK₨353.4m (up 51% from 2Q 2023). Profit margin: 5.8% (up from 4.9% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Nov 01
Shifa International Hospitals Limited Announces Directorial Changes Shifa International Hospitals Ltd. has made an important change in its board of directors, according to a financial announcement to the Pakistan Stock Exchange (PSE). Mr. Ioan Philippe Cleaton-Jones has been appointed as a Director of the company, effective from October 28, 2023. He is taking over the position from Dr. Jean Christophe Renondin. The announcement did not provide further details about the background of Mr. Ioan Philippe Cleaton-Jones or the reasons for Dr. Jean Christophe Renondin's departure. Reported Earnings • Nov 01
First quarter 2024 earnings released: EPS: PK₨5.93 (vs PK₨5.94 in 1Q 2023) First quarter 2024 results: EPS: PK₨5.93 (down from PK₨5.94 in 1Q 2023). Revenue: PK₨6.02b (up 27% from 1Q 2023). Net income: PK₨375.0m (flat on 1Q 2023). Profit margin: 6.2% (down from 7.9% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • Sep 07
Shifa International Hospitals Limited (KASE:SHFA) agreed to acquire SIHT Private Limited from Shifa Foundation. Shifa International Hospitals Limited (KASE:SHFA) agreed to acquire SIHT Private Limited from Shifa Foundation on September 7, 2023. The Competition Commission of Pakistan has granted approval to acquire SIHT Private Limited. Announcement • Aug 27
Shifa International Hospitals Limited Appoints Khawaja Junaid Mustafa as New Chief Medical Officer Shifa International Hospitals Limited announced the appointment of Dr. Khawaja Junaid Mustafa as the new Chief Medical Officer. Dr. Junaid is an accomplished certified medical professional with extensivetraining and expertise in Emergency Medicine. He further honed his skills by earning a fellowship from theCollege of Physicians and Surgeons in Emergency Medicine in Pakistan, and a certified professional in healthcarequality certification from the USA. He was trained and qualified in the United Kingdom and is a member of theRoyal College of Emergency Medicine in the UK. He is the President of the Pakistan Society of Emergency Medicine, a role in which he works to promote thedevelopment and advancement of Emergency Medicine in Pakistan. Dr. Junaid has also served as the Faculty Lead of Emergency Medicine at the College of Physicians and Surgeons in Pakistan (CPSP) for six years. Dr. Junaid brings a wealth of experience and knowledge to his new role. In his previous roles at ShifaInternational Hospital, he has worked as a Consultant and Program Director in Emergency Medicine and served asthe Director of Clinical Risk Management. He is also an Assistant Professor of Emergency Medicine at ShifaCollege of Medicine. Reported Earnings • Feb 28
Second quarter 2023 earnings released: EPS: PK₨3.71 (vs PK₨5.91 in 2Q 2022) Second quarter 2023 results: EPS: PK₨3.71 (down from PK₨5.91 in 2Q 2022). Revenue: PK₨4.87b (up 21% from 2Q 2022). Net income: PK₨234.6m (down 37% from 2Q 2022). Profit margin: 4.8% (down from 9.3% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 17% share price gain to PK₨122, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total loss to shareholders of 63% over the past three years. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 2 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Javed Siddiqui was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Oct 12
Upcoming dividend of PK₨1.50 per share Eligible shareholders must have bought the stock before 19 October 2022. Payment date: 18 November 2022. Payout ratio is a comfortable 7.9% but the company is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of Pakistani dividend payers (12%). Higher than average of industry peers (1.7%). Upcoming Dividend • May 03
Upcoming dividend of PK₨1.50 per share Eligible shareholders must have bought the stock before 10 May 2022. Payment date: 02 June 2022. Trailing yield: 1.7%. Lower than top quartile of Pakistani dividend payers (10%). In line with average of industry peers (1.6%). Reported Earnings • May 01
Third quarter 2022 earnings released: EPS: PK₨4.47 (vs PK₨4.77 in 3Q 2021) Third quarter 2022 results: EPS: PK₨4.47 (down from PK₨4.77 in 3Q 2021). Revenue: PK₨4.17b (up 6.5% from 3Q 2021). Net income: PK₨282.6m (down 6.2% from 3Q 2021). Profit margin: 6.8% (down from 7.7% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 2 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Javed Siddiqui was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • May 03
Third quarter 2021 earnings released: EPS PK₨4.86 (vs PK₨3.46 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: PK₨3.94b (up 16% from 3Q 2020). Net income: PK₨301.4m (up 42% from 3Q 2020). Profit margin: 7.6% (up from 6.2% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 06
Second quarter 2021 earnings released: EPS PK₨2.54 (vs PK₨3.19 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: PK₨3.53b (up 1.4% from 2Q 2020). Net income: PK₨157.4m (down 20% from 2Q 2020). Profit margin: 4.5% (down from 5.6% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Jan 19
New 90-day high: PK₨240 The company is up 3.0% from its price of PK₨233 on 21 October 2020. The Pakistani market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 13% over the same period. Reported Earnings • Nov 04
First quarter 2021 earnings released: EPS PK₨1.75 The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: PK₨3.14b (down 3.8% from 1Q 2020). Net income: PK₨108.3m (down 24% from 1Q 2020). Profit margin: 3.4% (down from 4.3% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Nov 03
New 90-day low: PK₨211 The company is down 19% from its price of PK₨260 on 05 August 2020. The Pakistani market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 2.0% over the same period. Reported Earnings • Oct 28
First quarter earnings released Over the last 12 months the company has reported total losses of PK₨33.2m, with earnings decreasing by PK₨788.6m from the prior year. Total revenue was PK₨12.1b over the last 12 months, down 1.0% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 08
Annual earnings released: Revenue misses expectations Annual revenue missed analyst estimates by 6.1% at PK₨12.3b. Revenue is forecast to grow 17% over the next year, compared to a 23% growth forecast for the Healthcare industry in Pakistan. Reported Earnings • Oct 08
Full year earnings released - EPS PK₨0.012 Over the last 12 months the company has reported total profits of PK₨731.0k, down 100% from the prior year. Total revenue was PK₨12.3b over the last 12 months, up 4.1% from the prior year. Announcement • Oct 06
Shifa International Hospitals Limited Proposes No Dividend for the Year 2020 Shifa International Hospitals Limited announced that due to current economic conditions and COVID-19 pandemic, the Company has not proposed any dividend for the year ended June 30, 2020. Is New 90 Day High Low • Sep 30
New 90-day low: PK₨228 The company is down 10.0% from its price of PK₨254 on 02 July 2020. The Pakistani market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 6.0% over the same period. Reported Earnings • Sep 30
Full year earnings released - EPS PK₨0.01 Over the last 12 months the company has reported total profits of PK₨731.0k, down 100% from the prior year. Total revenue was PK₨12.4b over the last 12 months, up 5.5% from the prior year. 
